Regeneron Pharmaceuticals Announces Dupixent Approved In The U.S. As The First-Ever Biologic Medicine For Patients With COPD
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals and Sanofi have announced that the FDA has approved Dupixent as the first biologic medicine for treating COPD with an eosinophilic phenotype in the U.S. This approval follows successful Phase 3 trials and previous approvals in the EU and China.
September 27, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals' Dupixent has been approved by the FDA as the first biologic for COPD with an eosinophilic phenotype, potentially boosting its market presence and sales.
The FDA approval of Dupixent for COPD is a significant milestone for Regeneron, as it expands the drug's indications and could lead to increased sales and market share. The approval is based on successful Phase 3 trials, indicating strong efficacy, which is likely to positively influence investor sentiment and the stock price.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90